Financials Consun Pharmaceutical Group Limited Deutsche Boerse AG

Equities

Delayed Deutsche Boerse AG Other stock markets 02:05:34 2024-06-05 EDT			5-day change	1st Jan Change
0.85 ^EUR	+3.03%		+31.78%	+60.38%

05-31	Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023	CI
05-24	Consun Pharmaceutical Group Limited Announces Special Dividend, Payable on 21 June 2024	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	3,507	2,053	2,848	2,820	3,436	5,072	-	-
Enterprise Value (EV) ¹	2,677	2,053	2,848	820.3	1,191	2,383	1,850	1,251
P/E ratio	44.4 x	4.21 x	4.91 x	4.16 x	4.42 x	5.57 x	4.79 x	4.16 x
Yield	4.41%	9.15%	-	7.29%	9.61%	7.48%	8.78%	10.1%
Capitalization / Revenue	2.03 x	1.17 x	-	1.21 x	1.33 x	1.73 x	1.52 x	1.33 x
EV / Revenue	1.55 x	1.17 x	-	0.35 x	0.46 x	0.81 x	0.55 x	0.33 x
EV / EBITDA	4.76 x	3.03 x	-	1.1 x	1.43 x	2.17 x	1.45 x	0.86 x
EV / FCF	13,151,706 x	2,508,919 x	-	-	-	-	-	-
FCF Yield	0%	0%	-	-	-	-	-	-
Price to Book	1.76 x	0.95 x	-	0.94 x	0.96 x	1.11 x	0.96 x	0.83 x
Nbr of stocks (in thousands)	845,733	799,826	794,304	788,390	792,434	824,229	-	-
Reference price ²	4.147	2.567	3.585	3.577	4.335	6.153	6.153	6.153
Announcement Date	3/23/20	3/23/21	3/23/22	3/23/23	3/28/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	1,728	1,753	-	2,340	2,590	2,930	3,333	3,812
EBITDA ¹	562	676.9	-	744.8	832	1,097	1,274	1,455
EBIT ¹	488.8	605.1	-	668.4	753.9	1,017	1,192	1,371
Operating Margin	28.29%	34.52%	-	28.57%	29.11%	34.71%	35.76%	35.98%
Earnings before Tax (EBT) ¹	133.7	583.7	-	746.4	863.7	1,028	1,205	1,386
Net income ¹	79.82	498.8	590.2	682.9	784.5	897.2	1,045	1,201
Net margin	4.62%	28.46%	-	29.19%	30.29%	30.62%	31.36%	31.52%
EPS ²	0.0934	0.6100	0.7300	0.8600	0.9800	1.105	1.285	1.480
Free Cash Flow	203.6	818.4	-	-	-	-	-	-
FCF margin	11.78%	46.69%	-	-	-	-	-	-
FCF Conversion (EBITDA)	36.23%	120.89%	-	-	-	-	-	-
FCF Conversion (Net income)	255.04%	164.07%	-	-	-	-	-	-
Dividend per Share ²	0.1828	0.2349	-	0.2606	0.4164	0.4600	0.5400	0.6200
Announcement Date	3/23/20	3/23/21	3/23/22	3/23/23	3/28/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-	-	-	-
Net Cash position ¹	830	-	-	2,000	2,245	2,689	3,222	3,821
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow	204	818	-	-	-	-	-	-
ROE (net income / shareholders' equity)	3.85%	23.7%	-	23.7%	23.2%	23.6%	23.8%	24.2%
ROA (Net income/ Total Assets)	2.1%	13%	-	14.8%	15.1%	16%	16.3%	17.1%
Assets ¹	3,803	3,829	-	4,628	5,200	5,625	6,412	7,026
Book Value Per Share ²	2.350	2.700	-	3.800	4.540	5.560	6.420	7.400
Cash Flow per Share ²	-	-	-	-	1.020	1.120	1.290	1.480
Capex ¹	180	48.7	-	-	52.6	119	144	184
Capex / Sales	10.4%	2.78%	-	-	2.03%	4.06%	4.32%	4.83%
Announcement Date	3/23/20	3/23/21	3/23/22	3/23/23	3/28/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.153 CNY

Average target price

7.615 CNY

Spread / Average Target

+23.76%

	1st Jan change	Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD.	+18.09%	41.07B
OTSUKA HOLDINGS CO., LTD.	+24.16%	22.65B
SANDOZ GROUP AG	+14.86%	15.02B
CIPLA LIMITED	+20.11%	14.14B
ZYDUS LIFESCIENCES LIMITED	+52.15%	12.09B
ONO PHARMACEUTICAL CO., LTD.	-10.97%	6.91B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+15.28%	5.59B